Основная статистика
| CIK | 1419051 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Therapeutic Solutions International, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| May 16, 2025 |
UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0167 Washington, D. |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0080 Expires: May 31, 2027 Estimated average burden Hours per response. 2.50 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 000-54554 Therapeutic Solutions International, Inc. OTC Markets (Exact na |
|
| April 24, 2025 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 23, 2025 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-54554 45-1226465 (State or other jurisdiction of incorporati |
|
| April 24, 2025 |
Exhibit 99.1 |
|
| April 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CE ☐ Form N-CSR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Per |
|
| February 28, 2025 |
Exhibit 99.1 |
|
| February 28, 2025 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2025 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-54554 45-1226465 (State or other jurisdiction of incorpor |
|
| February 18, 2025 |
Exhibit 99.1 |
|
| February 18, 2025 |
Exhibit 99.2 |
|
| February 18, 2025 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 15, 2025 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-54554 45-1226465 (State or other jurisdiction of incorpor |
|
| January 10, 2025 |
Exhibit 99.1 |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 07, 2025 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-54554 45-1226465 (State or other jurisdiction of incorpora |
|
| November 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported November 25, 2024 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-54554 45-1226465 (State or other jurisdiction of incorporat |
|
| November 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54554 Therapeutic Solu |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CE ☐ Form N-CSR For Period Ended: September 30, 2024 ☐ Transition Report on Form 10K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Per |
|
| August 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54554 Therapeutic Solutions |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CE ☐ Form N-CSR For Period Ended: June 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period |
|
| July 31, 2024 |
TSOI Notice of Election of the Dividend of CNSI Common Stock Form Exhibit 99.1 |
|
| July 31, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 28, 2024 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-54554 45-1226465 (State or other jurisdiction of incorporatio |
|
| July 1, 2024 |
TSOI Notice to DTCC Brokers Re Shareholder Div. Election with Form Exhibit 99.1 |
|
| July 1, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 28, 2024 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-54554 45-1226465 (State or other jurisdiction of incorporatio |
|
| May 31, 2024 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 31, 2024 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-54554 45-1226465 (State or other jurisdiction of incorporation |
|
| May 31, 2024 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 31, 2024 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-54554 45-1226465 (State or other jurisdiction of incorporati |
|
| May 31, 2024 |
Exclusive Patent License Agreement between TSOI and CNSI Patent Publication No. 20220280574. Exhibit 10.1 |
|
| May 31, 2024 |
Exclusive Patent License Agreement between TSOI and CNSI Patent Publication No. 20220280574. Exhibit 10.1 |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54554 Therapeutic Solution |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CE ☐ Form N-CSR For Period Ended: March 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period |
|
| May 6, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 3, 2024 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-54554 45-1226465 (State or other jurisdiction of incorporation |
|
| May 6, 2024 |
Minutes of Resolutions of the Board of Directors of Campbell Neurosciences, Inc. Exhibit 99.2 |
|
| May 6, 2024 |
Minutes of Resolutions of the Board of Directors of Therapeutic Solutions International, Inc. Exhibit 99.1 |
|
| April 17, 2024 |
Exhibit 3.1 |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54554 Therapeutic Solutions Int |
|
| April 17, 2024 |
Certificate of Merger, filed February 22, 2011 Exhibit 3.1.1 |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CE ☐ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Per |
|
| February 21, 2024 |
Certificate of Amendment to Articles of Incorporation, filed February 20, 2024 Exhibit 99.1 |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 21, 2024 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-54554 45-1226465 (State or other jurisdiction of incorpor |
|
| February 20, 2024 |
Certificate of Change Pursuant to NRS 78.1955, filed February 15, 2024 Exhibit 3.1 |
|
| February 20, 2024 |
Attachment to Certificate of Designation Exhibit 3.11 |
|
| February 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 20, 2024 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-54554 45-1226465 (State or other jurisdiction of incorpor |
|
| February 6, 2024 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Therapeutic Solutions International, Inc. |
|
| February 6, 2024 |
Exhibit 3.1 |
|
| February 6, 2024 |
Securities Purchase Agreement (PA) Exhibit 1.1 |
|
| February 6, 2024 |
Subsidiaries of the registrant Exhibit 21.1 |
|
| February 6, 2024 |
Exhibit 3.2 |
|
| February 6, 2024 |
Exhibit 3.3 |
|
| February 6, 2024 |
701 Wild Rose Lane Elk City, ID 83525 4093 Oceanside Blvd, Suite B Oceanside, California 92056 Ph: 760-295-7208 VIA EDGAR Securities and Exchange Commission February 5, 2024 Division of Corporation Finance 100 F Street N. |
|
| February 6, 2024 |
As filed with the Securities and Exchange Commission on February 5, 2024 As filed with the Securities and Exchange Commission on February 5, 2024 Registration No. |
|
| February 6, 2024 |
Letter re unaudited interim financial information EXHIBIT 15.1 LETTER RE UNAUDITED INTERIM FINANCIAL INFORMATION February 6, 2024 Therapeutic Solutions International, Inc. 701 Wild Rose Lane Elk City, Idaho 83525 To the Board of Directors of Therapeutic Solutions International, Inc. We have reviewed, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the unaudited interim financial information of Th |
|
| January 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported January 22, 2024 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-54554 45-1226465 (State or other jurisdiction of incorporati |
|
| January 17, 2024 |
Exhibit 3.2 |
|
| January 17, 2024 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Therapeutic Solutions International, Inc. |
|
| January 17, 2024 |
Letter re unaudited interim financial information Exhibit 15.1 |
|
| January 17, 2024 |
Attorney Opinion Letter re: S-1 Exhibit 5.1 |
|
| January 17, 2024 |
Securities Purchase Agreement (PA) Exhibit 1.1 |
|
| January 17, 2024 |
Subsidiaries of the registrant Exhibit 21.1 Campbell Neurosciences, Inc. On February 1, 2021, the Company formed Campbell Neurosciences Inc. The Company has signed license agreements with Campbell Neurosciences Inc., a partially owned company, for access to the 9 patents filed related to the previous Campbell Neurosciences Division and two subsequent. Additionally, Campbell Neurosciences Inc. has entered into purchase agreement |
|
| January 17, 2024 |
United States SECURITIES AND EXCHANGE COMMISSION FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Therapeutic Solutions International, Inc. |
|
| January 17, 2024 |
Exhibit 3.1 |
|
| January 17, 2024 |
Exhibit 3.3 |
|
| January 12, 2024 |
701 Wild Rose lane Elk City, ID 83525 4093 Oceanside Blvd. Suite B Oceanside, CA 92056 701 Wild Rose lane Elk City, ID 83525 4093 Oceanside Blvd. Suite B Oceanside, CA 92056 United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, NE Washington, D.C. 20549-6010 RE: Therapeutic Solutions International, Inc., Rule 477 Application for Withdrawal of Post-Effective Amendment No. 1 to Registration Statement (File No. 333-268070) Dear Sir/Madam; Pursu |
|
| January 4, 2024 |
Subsidiaries of the registrant Exhibit 21.1 |
|
| January 4, 2024 |
Letter re unaudited interim financial information Exhibit 15.1 |
|
| January 4, 2024 |
United States SECURITIES AND EXCHANGE COMMISSION POST-EFFECTIVE AMENDMENT NO. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Therapeutic Solutions International, Inc. (Exact name of Registrant as Specified in Its Charter) Nevada 2833 45-1226465 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Empl |
|
| December 22, 2023 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 22, 2023 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-54554 45-1226465 (State or other jurisdiction of incorpor |
|
| December 22, 2023 |
AMICUS CURIAE BRIEF OF TIMOTHY G. DIXON Exhibit 99 |
|
| December 22, 2023 |
SUPPLEMENTAL AMICUS CURIAE BRIEF OF TIMOTHY G. DIXON Exhibit 99.1 |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54554 Therapeutic Solu |
|
| October 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 13, 2023 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-54554 45-1226465 (State or other jurisdiction of incorpora |
|
| October 13, 2023 |
Certificate of Amendment to Articles of Incorporation, filed October 11, 2023. Exhibit 99.1 |
|
| September 13, 2023 |
Exclusive Patent License Agreement between TSOI and CNSI 63-077723 Exhibit 99.9 |
|
| September 13, 2023 |
Exclusive Patent License Agreement between TSOI and CNSI 63-068388 Exhibit 99.7 |
|
| September 13, 2023 |
Exclusive Patent License Agreement between TSOI and CNSI 63-174291 Exhibit 99.13 |
|
| September 13, 2023 |
Exclusive Patent License Agreement between TSOI and CNSI 17-030416 Exhibit 99.4 |
|
| September 13, 2023 |
Purchase Agreement between TSOI and CNSI Exhibit 99.3 |
|
| September 13, 2023 |
Exclusive Patent License Agreement between TSOI and CNSI 63-189630 Exhibit 99.14 |
|
| September 13, 2023 |
Exclusive Patent License Agreement between TSOI and CNSI 63-071381 Exhibit 99.8 |
|
| September 13, 2023 |
Exclusive Patent License Agreement between TSOI and CNSI 63-057315 Exhibit 99.5 |
|
| September 13, 2023 |
Minutes and Resolutions of the Board of Directors of Campbell Neurosciences, Inc. Exhibit 99.2 |
|
| September 13, 2023 |
Exclusive Patent License Agreement between TSOI and CNSI 63-122862 Exhibit 99.11 |
|
| September 13, 2023 |
Minutes and Resolutions of the Board of Directors of Therapeutic Solutions International, Inc. Exhibit 99.1 |
|
| September 13, 2023 |
Exclusive Patent License Agreement between TSOI and CNSI 63-128759 Exhibit 99.12 |
|
| September 13, 2023 |
Exclusive Patent License Agreement between TSOI and CNSI 63-105964 Exhibit 99.10 |
|
| September 13, 2023 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 12, 2023 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-54554 45-1226465 (State or other jurisdiction of incorpo |
|
| September 13, 2023 |
Exclusive Patent License Agreement between TSOI and CNSI 63-061202 Exhibit 99.6 |
|
| August 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54554 Therapeutic Solutions |
|
| August 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CE ☐ Form N-CSR For Period Ended: June 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period |
|
| July 27, 2023 |
Exhibit 10.1 |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 26, 2023 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-54554 45-1226465 (State or other jurisdiction of incorporatio |
|
| July 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 07, 2023 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-54554 45-1226465 (State or other jurisdiction of incorporatio |
|
| July 7, 2023 |
Exhibit 10.1 |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CE ☐ Form N-CSR For Period Ended: March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54554 Therapeutic Solution |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54554 Therapeutic Solutions Int |
|
| March 27, 2023 |
701 Wild Rose Lane Elk City, Idaho 83525 4093 Oceanside Blvd. Suite B Oceanside CA 92056 Exhibit 99.3 701 Wild Rose Lane Elk City, Idaho 83525 4093 Oceanside Blvd. Suite B Oceanside CA 92056 DIVIDEND OFFER AND ACCEPTANCE FORM Dear Shareholder, On or about March 21, 2023 the Board of Directors of Therapeutic Solutions International, Inc. (“TSOI”), by unanimous approval, and with the unanimous approval of the Preferred A Stock holders representing at least 51% of all shareholders with t |
|
| March 27, 2023 |
Exhibit 99.2 |
|
| March 27, 2023 |
Exhibit 99.1 |
|
| March 27, 2023 |
Exhibit 99.4 SHAREHOLDER RIGHTS AGREEMENT THIS SHAREHOLDER RIGHTS AGREEMENT (the “Agreement” and/or “Shareholder Agreement”), is made by and among (“TSOI Investor” and/or “Share2”), Therapeutic Solutions International, Inc., (“TSOI” and/or “Share1”), hereinafter sometimes referred to individually as a “Shareholder” and collectively as the “Shareholders”) and Campbell Neurosciences, Inc., a Delawar |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 24, 2023 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-54554 45-1226465 (State or other jurisdiction of incorporati |
|
| February 21, 2023 |
Exhibit 10.1 |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 21, 2023 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-54554 45-1226465 (State or other jurisdiction of incorpor |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 21, 2023 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-54554 45-1226465 (State or other jurisdiction of incorpor |
|
| February 21, 2023 |
Exhibit 10.1 |
|
| February 15, 2023 |
TSOI / Therapeutic Solutions International Inc / Jadi Cell, LLC - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 jadic13ga.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1) Under the Securities Exchange Act of 1934 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 883378101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| February 13, 2023 |
701 Wild Rose Lane Elk City, ID, 83525 4093 Oceanside Blvd. Suite B Oceanside, CA, 92056 701 Wild Rose Lane Elk City, ID, 83525 4093 Oceanside Blvd. Suite B Oceanside, CA, 92056 VIA EDGAR Securities and Exchange Commission February 13, 2023 Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Attention: Erik Gerding, Director Jordan Nimitz, Staff Attorney Re: Therapeutic Solutions International, Inc. (TSOI) Registration Statement on Form S-1/A File No. 333-268070 R |
|
| February 10, 2023 |
Exhibit 99.4 |
|
| February 10, 2023 |
Letter to University Miami dated January 11, 2023 Exhibit 99.1 |
|
| February 10, 2023 |
Letter to JadiCell LLC dated January 20, 2023 Exhibit 99.3 |
|
| February 10, 2023 |
Letter to JadiCell LLC dated January 5, 2023 Exhibit 99.2 |
|
| February 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 10, 2023 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-54554 45-1226465 (State or other jurisdiction of incorpor |
|
| February 7, 2023 |
Letter re unaudited interim financial information Exhibit 15.1 |
|
| February 7, 2023 |
EX-3.1 3 ex3-1.htm Exhibit 3.1 |
|
| February 7, 2023 |
Securities Purchase Agreement (PA) Exhibit 1.1 |
|
| February 7, 2023 |
United States SECURITIES AND EXCHANGE COMMISSION FORM S-1 REGISTRATION STATEMENT AMENDMENT FOUR (4) UNDER THE SECURITIES ACT OF 1933 Therapeutic Solutions International, Inc. |
|
| February 7, 2023 |
Calculation of Filing Fee Tables, Amend 2 Exhibit 107.1 Calculation of Filing Fee Tables Form S-1A Amendment Two (2) (Form Type) Therapeutic Solutions International, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee R |
|
| February 7, 2023 |
EX-3.3 5 ex3-3.htm Exhibit 3.3 |
|
| February 7, 2023 |
CORRESP 1 filename1.htm 701 Wild Rose Lane Elk City, ID, 83525 4093 Oceanside Blvd. Suite B Oceanside, CA, 92056 U.S. Securities and Exchange Commission Division of Corporate Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549-7561 Re: Therapeutic Solutions International, Inc. (TSOI) Registration Statement on Form S-1A File No.: 333-268070 February 7, 2 |
|
| February 7, 2023 |
EX-3.2 4 ex3-2.htm Exhibit 3.2 |
|
| February 7, 2023 |
Subsidiaries of the registrant Exhibit 21.1 Campbell Neurosciences, Inc. On February 1, 2021, the Company formed Campbell Neurosciences Inc. The Company has signed license agreements with Campbell Neurosciences Inc., a partially owned company, for access to the 9 patents filed related to the previous Campbell Neurosciences Division. The patents are: 1. 63/128759 Immunotherapy for Opioid Addiction 2. 63/122862 Treatment of Major |
|
| January 31, 2023 |
EX-3.1 3 ex3-1.htm Exhibit 3.1 |
|
| January 31, 2023 |
Subsidiaries of the registrant Exhibit 21.1 Campbell Neurosciences, Inc. On February 1, 2021, the Company formed Campbell Neurosciences Inc. The Company has signed license agreements with Campbell Neurosciences Inc., a partially owned company, for access to the 9 patents filed related to the previous Campbell Neurosciences Division. The patents are: 1. 63/128759 Immunotherapy for Opioid Addiction 2. 63/122862 Treatment of Major |
|
| January 31, 2023 |
Exhibit 3.2 |
|
| January 31, 2023 |
Calculation of Filing Fee Tables, Amend 2 EX-FILING FEES 10 ex-107.htm CALCULATION OF FILING FEE TABLES Exhibit 107.1 Calculation of Filing Fee Tables Form S-1A Amendment Two (2) (Form Type) Therapeutic Solutions International, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offeri |
|
| January 31, 2023 |
Exhibit 3.3 |
|
| January 31, 2023 |
Securities Purchase Agreement (PA) Exhibit 1.1 |
|
| January 31, 2023 |
United States SECURITIES AND EXCHANGE COMMISSION FORM S-1 REGISTRATION STATEMENT AMENDMENT THREE (3) UNDER THE SECURITIES ACT OF 1933 Therapeutic Solutions International, Inc. |
|
| January 31, 2023 |
Letter re unaudited interim financial information Exhibit 15.1 |
|
| January 30, 2023 |
CORRESP 1 filename1.htm 701 Wild Rose Lane Elk City, ID, 83525 4093 Oceanside Blvd. Suite B Oceanside, CA, 92056 U.S. Securities and Exchange Commission Division of Corporate Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549-7561 Re: Therapeutic Solutions International, Inc. (TSOI) Registration Statement on Form S-1A File No.: 333-268070 January 30, 2 |
|
| January 18, 2023 |
CORRESP 1 filename1.htm 701 Wild Rose Lane Elk City, ID, 83525 4093 Oceanside Blvd. Suite B Oceanside, CA, 92056 U.S. Securities and Exchange Commission Division of Corporate Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549-7561 Re: Therapeutic Solutions International, Inc. (TSOI) Registration Statement on Form S-1A File No.: 333-268070 Ladies and Ge |
|
| January 18, 2023 |
United States SECURITIES AND EXCHANGE COMMISSION FORM S-1 REGISTRATION STATEMENT AMENDMENT TWO (2) UNDER THE SECURITIES ACT OF 1933 Therapeutic Solutions International, Inc. |
|
| January 18, 2023 |
Exhibit 3.1 |
|
| January 18, 2023 |
Subsidiaries of the registrant Exhibit 21.1 Campbell Neurosciences, Inc. On February 1, 2021, the Company formed Campbell Neurosciences Inc. The Company has signed license agreements with Campbell Neurosciences Inc., a partially owned company, for access to the 9 patents filed related to the previous Campbell Neurosciences Division. The patents are: 1. 63/128759 Immunotherapy for Opioid Addiction 2. 63/122862 Treatment of Major |
|
| January 18, 2023 |
Letter re unaudited interim financial information Exhibit 15.1 |
|
| January 18, 2023 |
Securities Purchase Agreement (PA) Exhibit 1.1 |
|
| January 18, 2023 |
Exhibit 3.3 |
|
| January 18, 2023 |
EX-3.2 4 ex3-2.htm Exhibit 3.2 |
|
| January 18, 2023 |
Calculation of Filing Fee Tables, Amend 2 Exhibit 107.1 Calculation of Filing Fee Tables Form S-1A Amendment Two (2) (Form Type) Therapeutic Solutions International, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee R |
|
| December 13, 2022 |
CORRESP 1 filename1.htm December 13, 2022 U.S. Securities and Exchange Commission Division of Corporate Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549-7561 Re: Therapeutic Solutions International, Inc. (TSOI) Registration Statement on Form S-1A File No.: 333-268070 Ladies and Gentlemen: This correspondence is Therapeutic Solutions International, In |
|
| December 8, 2022 |
Exhibit 3.2 |
|
| December 8, 2022 |
Calculation of Filing Fee Tables EX-FILING FEES 10 ex107.htm Exhibit 107 Calculation of Filing Fee Tables Form S-1A Amendment 1 (Form Type) Therapeutic Solutions International, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Off |
|
| December 8, 2022 |
As filed with the Securities and Exchange Commission on December 8, 2022 As filed with the Securities and Exchange Commission on December 8, 2022 Registration No. |
|
| December 8, 2022 |
Letter re unaudited interim financial information Exhibit 15.1 |
|
| December 8, 2022 |
Subsidiaries of the registrant Exhibit 21.1 Campbell Neurosciences, Inc. On February 1, 2021, the Company formed Campbell Neurosciences Inc. The Company has signed license agreements with Campbell Neurosciences Inc., a partially owned company, for access to the 9 patents filed related to the previous Campbell Neurosciences Division. The patents are: 1. 63/128759 Immunotherapy for Opioid Addiction 2. 63/122862 Treatment of Major |
|
| December 8, 2022 |
Securities Purchase Agreement (PA) Exhibit 1.1 |
|
| December 8, 2022 |
Exhibit 3.3 |
|
| December 8, 2022 |
EX-3.1 3 ex3-1.htm Exhibit 3.1 |
|
| December 6, 2022 |
Certificate of Change Pursuant to NRS 78.209, filed December 02, 2022 Exhibit 3.1 |
|
| December 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 01, 2022 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-54554 45-1226465 (State or other jurisdiction of incorpor |
|
| November 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54554 Therapeutic Solu |
|
| November 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CE ☐ Form N-CSR For Period Ended: September 30, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Pe |
|
| November 1, 2022 |
701 Wild Rose Lane Elk City, ID 83525 4093 Oceanside Blvd. Suite B Oceanside, CA 92056 VIA EDGAR November 1, 2022 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549-3561 RE: Therapeutic Solutions International, Inc. Withdrawal of Registration Statement on Form S-3 File No. 333-267636 Ladies and Gentlemen: Pursuant to Rule 477 pr |
|
| October 31, 2022 |
Securities Purchase Agreement (PA) Exhibit 1.1 |
|
| October 31, 2022 |
As filed with the Securities and Exchange Commission on October 31, 2022 As filed with the Securities and Exchange Commission on October 31, 2022 Registration No. |
|
| October 31, 2022 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered Proposed Max Offering Price Per Unit Proposed Maximum Aggregate Offering Price Amount Registration Fee Common Stock TBD Market (1) $ 0. |
|
| October 31, 2022 |
Exhibit 13.2 |
|
| October 25, 2022 |
Restem.com article published at Exhibit 99.2 |
|
| October 25, 2022 |
Exhibit 99.12 |
|
| October 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 24, 2022 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-54554 45-1226465 (State or other jurisdiction of incorpora |
|
| October 25, 2022 |
EX-99.18 96 ex99-18.htm Exhibit 99.18 |
|
| October 25, 2022 |
Email from W. Michael Black, legal counsel for JadiCell LLC. EX-99 2 ex99.htm Exhibit 99 |
|
| October 25, 2022 |
Convertible Note between TSOI and JadiCell LLC Exhibit 99.13 |
|
| October 25, 2022 |
Paper co-authored by Camillo Ricordi and Keith March from Restem Exhibit 99.21 |
|
| October 25, 2022 |
Letter from Thomas Ichim to FDA Exhibit 99.17 |
|
| October 25, 2022 |
News article dated May 7, 2020 Exhibit 99.19 |
|
| October 25, 2022 |
Exhibit 99.1 |
|
| October 25, 2022 |
Exhibit 99.14 |
|
| October 25, 2022 |
Letter from Camillo Ricordi to FDA Exhibit 99.16 |
|
| September 27, 2022 |
Calculation of Filing Fee Tables Form S-3 (Form Type) Therapeutic Solutions International, Inc. |
|
| September 27, 2022 |
Exhibit 4.1 |
|
| September 27, 2022 |
Certificate of Amendment to Designation - After Issuance of Class or Series Exhibit 4.4 |
|
| September 27, 2022 |
Form of Stock Purchase Agreement Exhibit 4.9 |
|
| September 27, 2022 |
As filed with the Securities and Exchange Commission on September 23, 2022 As filed with the Securities and Exchange Commission on September 23, 2022 Registration No. |
|
| September 20, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 19, 2022 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-54554 45-1226465 (State or other jurisdiction of incorpo |
|
| September 20, 2022 |
(99.2) Press release dated September 20, 2022, issued by Therapeutic Solutions International, Inc. Exhibit 99.2 |
|
| September 20, 2022 |
(99.1) TSOI Securities Purchase Agreement Exhibit 99.1 |
|
| August 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54554 Therapeutic Solutions |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CE ☐ Form N-CSR For Period Ended: June 30, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period |
|
| May 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54554 Therapeutic Solution |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NT 10-Q 1 formnt10-q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CE ☐ Form N-CSR For Period Ended: March 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period En |
|
| May 11, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 10, 2022 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-54554 45-1226465 (State or other jurisdiction of incorporation |
|
| May 11, 2022 |
Executed Exclusive Patent License Agreement Exhibit 99 |
|
| May 2, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 2, 2022 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-54554 45-1226465 (State or other jurisdiction of incorporation |
|
| May 2, 2022 |
Executed Master Services Agreement Exhibit 99.1 |
|
| May 2, 2022 |
Press release dated May 2, 2022, issued by Therapeutic Solutions International, Inc. Exhibit 99.2 |
|
| April 20, 2022 |
TSOI / Therapeutic Solutions International Inc / Jadi Cell, LLC - SCHEDULE 13G Passive Investment UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 883378101 (CUSIP Number) February 23, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54554 Therapeutic Solutions Int |
|
| March 30, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A AMENDMENT CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 30, 2022 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-54554 45-1226465 (State or other jurisdiction of |
|
| March 30, 2022 |
Exhibit 99 |
|
| March 25, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 25, 2022 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-54554 45-1226465 (State or other jurisdiction of incorporati |
|
| March 25, 2022 |
Press release dated March 25, 2022, issued by Therapeutic Solutions International, Inc. Exhibit 99 |
|
| March 4, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 4, 2022 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-54554 45-1226465 (State or other jurisdiction of incorporatio |
|
| November 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 000-54554 THERAPEUTIC SOLUTIO |
|
| November 16, 2021 |
UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0058 Washington, D. |
|
| September 20, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 20, 2021 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-54554 45-1226465 (State or other jurisdiction of incorpo |
|
| September 20, 2021 |
Convertible Note between TSOI and Jadi Cell, LLC, dated 11/29/2018. Exhibit 10.1 |
|
| August 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 000-54554 THERAPEUTIC SOLUTIONS IN |
|
| May 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 1 [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2021 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 000-54554 T |
|
| May 19, 2021 | ||
| May 19, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 15, 2021 THERAPEUTIC SOLUTONS INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-54554 45-1226465 (State or other jurisdiction of incorporatio |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2021 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 000-54554 THERAPEUTIC SOLUTIO |
|
| April 22, 2021 |
Annual Report - FORM 10-K/A AMENDED ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 2 [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54554 The |
|
| April 15, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 15, 2021 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-54554 45-1226465 (State or other jurisdiction of incorporati |
|
| April 15, 2021 | ||
| April 12, 2021 |
Annual Report - FORM 10-K/A AMENDED ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 1 [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54554 The |
|
| April 12, 2021 |
Annual Report - FORM 10-K/A AMENDED ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 1 [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54554 The |
|
| April 9, 2021 |
Annual Report - FORM 10-K ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54554 Therapeutic Solutions |
|
| March 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NT 10-K 1 latefilingnoticent10k.htm FORM 12B-25 NOTICE OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 OMB APPROVAL OMB Number: 3235-0058 Expires: 28-Feb-22 Estimated average burden hours per response 2.50 SEC FILE NUMBER CUSIP NUMBER (Check one): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-CE [ ] Form N-CSR Fo |
|
| March 8, 2021 |
Exhibit 99 |
|
| March 8, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 8, 2021 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-54554 45-1226465 (State or other jurisdiction of incorporatio |
|
| February 26, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 26, 2021 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-54554 45-1226465 (State or other jurisdiction of incorpor |
|
| February 26, 2021 |
EX-99 2 f8k072820ex99.htm EXHIBIT 99 PRESS RELEASE DATED FEBRUARY 26, 2021, ISSUED BY THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. |
|
| February 4, 2021 |
Financial Statements and Exhibits, Other Events Form 8K Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 4, 2021 |
Exhibit 10.1 Sales Agreement between Therapeutic Solutions International, Inc., and Community Shield, LLC. |
|
| February 4, 2021 |
Exhibit 99.1 Press release dated February 04, 2021, issued by Therapeutic Solutions International, Inc. |
|
| December 30, 2020 |
Form 8K Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 30, 2020 |
EX-10.4 5 f8k123019ex10z4.htm EXHIBIT 10.4 UNANIMOUS WRITTEN CONSENT OF THE BOARD OF DIRECTORS OF CAMPBELL NEUROSCIENCES, INC. |
|
| December 30, 2020 |
EX-10.7 8 f8k123019ex10z7.htm EXHIBIT 10.7 PURCHASE AGREEMENT BETWEEN TSOI AND CNSI |
|
| December 30, 2020 |
EX-10.8 9 f8k123019ex10z8.htm EXHIBIT 10.8 EXCLUSIVE PATENT LICENSE AGREEMENT BETWEEN TSOI AND CNSI 17-030416 |
|
| December 30, 2020 |
Exhibit 10.12 Exclusive Patent License Agreement between TSOI and CNSI 63-071381 |
|
| December 30, 2020 |
EX-10.15 16 f8k123019ex10z15.htm EXHIBIT 10.15 EXCLUSIVE PATENT LICENSE AGREEMENT BETWEEN TSOI AND CNSI 63-122862 |
|
| December 30, 2020 |
EX-10.2 3 f8k123019ex10z2.htm EXHIBIT 10.2 UNANIMOUS WRITTEN CONSENT OF THE BOARD OF DIRECTORS OF THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. |
|
| December 30, 2020 |
EX-10.14 15 f8k123019ex10z14.htm EXHIBIT 10.14 EXCLUSIVE PATENT LICENSE AGREEMENT BETWEEN TSOI AND CNSI 63-105964 |
|
| December 30, 2020 |
EX-10.11 12 f8k123019ex10z11.htm EXHIBIT 10.11 EXCLUSIVE PATENT LICENSE AGREEMENT BETWEEN TSOI AND CNSI 63-068388 |
|
| December 30, 2020 |
EX-10.16 17 f8k123019ex10z16.htm EXHIBIT 10.16 EXCLUSIVE PATENT LICENSE AGREEMENT BETWEEN TSOI AND CNSI 63-128759 |
|
| December 30, 2020 |
Exhibit 10.3 Unanimous written consent of the Board of Directors of Sandbox Dental Labs, Inc. |
|
| December 30, 2020 |
EX-10.6 7 f8k123019ex10z6.htm EXHIBIT 10.6 MINUTES OF THE BOARD OF DIRECTORS OF CAMPBELL NEUROSCIENCES, INC. |
|
| December 30, 2020 |
Exhibit 10.1 Unanimous written consent of the Board of Directors of Sandbox Dental Labs, Inc. |
|
| December 30, 2020 |
Exhibit 10.10 Exclusive Patent License Agreement between TSOI and CNSI 63-061202 |
|
| December 30, 2020 |
Exhibit 10.9 Exclusive Patent License Agreement between TSOI and CNSI 63-057315 |
|
| December 30, 2020 |
EX-10.5 6 f8k123019ex10z5.htm EXHIBIT 10.5 MINUTES OF THE BOARD OF DIRECTORS OF CAMPBELL NEUROSCIENCES, INC. |
|
| December 30, 2020 |
EX-10.13 14 f8k123019ex10z13.htm EXHIBIT 10.13 EXCLUSIVE PATENT LICENSE AGREEMENT BETWEEN TSOI AND CNSI 63-077723 |
|
| December 18, 2020 |
Other Events - FORM 8-K/A AMENDED CURRENT REPORT Form 8-K/A Amended Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 18, 2020 |
8-K 1 8k1218208k.htm FORM 8K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 18, 2020 THERAPEUTIC SOLUTONS INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-54554 45-12264 |
|
| November 17, 2020 |
- FORM 12B-25 NOTICE OF LATE FILING Form 12b-25 Notice of Late Filing OMB APPROVAL OMB Number: 3235-0058 Expires: 28-Feb-22 Estimated average burden hours per response 2. |
|
| November 17, 2020 |
Form 10-Q Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| October 30, 2020 |
EX-99 2 f8k103020ex99.htm EXHIBIT 99 PRESS RELEASE DATED OCTOBER 28, 2020, ISSUED BY THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. |
|
| October 30, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8K CURRENT REPORT Form 8K Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 27, 2020 |
Post Effective Amendment UNITED STATES SECURITIES AND EXCHANGE COMMISSION POST-EFFECTIVE AMENDMENT NO. |
|
| October 7, 2020 |
- POST-EFFECTIVE AMENDMENT 1 ON FORM S-1 Post-Effective Amendment 1 on Form S-1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION POST-EFFECTIVE AMENDMENT NO. |
|
| August 24, 2020 |
Quarterly Report - FORM 10-Q/A AMENDED QUARTERLY REPORT Form 10-Q/A Amended Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 19, 2020 |
Quarterly Report - FORM 10-Q QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 000-54554 THERAPEUTIC SOLUTION |
|
| August 14, 2020 |
- FORM 12B-25 NOTICE OF LATE FILING Form 12b-25 Notice of Late Filing OMB APPROVAL OMB Number: 3235-0058 Expires: 28-Feb-22 Estimated average burden hours per response 2. |
|
| July 28, 2020 |
Financial Statements and Exhibits, Other Events Form 8K Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 28, 2020 |
SEC Correspondence U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7561 Re:Therapeutic Solutions International, Inc. (TSOI) Registration Statement on Form S-1 File No.: 333-236338 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Therapeutic Solutions International, Inc. (the “Registrant”) hereby requests that the |
|
| July 28, 2020 |
Exhibit 99 Press release dated July 28, 2020, issued by Therapeutic Solutions International, Inc. |
|
| July 10, 2020 |
Form S1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 2833 45-1226465 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Id |
|
| July 9, 2020 |
Quarterly Report - FORM 10-Q/A AMENDED QUARTERLY REPORT Form 10-Q/A Amended Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| July 6, 2020 |
Quarterly Report - FORM 10-Q QUARTERLY REPORT Form 10-Q Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| June 30, 2020 |
- FORM 12B-25 NOTICE OF LATE FILING Form 12b-25 Notice of Late Filing U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 000-54554 [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For period ended: March 31, 2020 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11- |
|
| June 9, 2020 |
Exhibit 99 Press release dated May 8, 2020, issued by Therapeutic Solutions International, Inc. |
|
| June 9, 2020 |
Financial Statements and Exhibits, Other Events Form 8K Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 29, 2020 |
Form 8-K Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
